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ABSTRACT 
 
Background 
The majority of children on highly active antiretroviral therapy achieve immune reconstitution 
and virologic control; however, there is a subset of individuals who clinically worsen on 
recovery. It is important to profile and characterize oral lesions in children on HAART as they 
may be clinical predictors of HAART failure or syndromes related to HAART. 
 
Method 
Two hundred and forty children aged between one month and 14 years were examined for oral  
lesions at the Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa. All  
patients were on HAART. The classification for presumptive diagnostic criteria for oral lesions  
was based on the review of Oral HIV/AIDS Research Alliance: updated case definitions of oral  
disease endpoints. Age (in months and years) at the time of examination and at diagnosis of HIV,  
duration of antiretroviral treatment (months), viral load ( RNH-HIV-1 per ml), CD4
+
 T- 
lymphocyte cell count (cells/mm
3
) and HAART regimen were recorded. 
 
Results 
 
Twenty two children out of 240 presented with either active lesions or scarring as a result of  
previous disease whilst on HAART, making up 9,2% prevalence rate of oral lesions in children  
on HAART in this cohort. This is significantly lower than prevalence rates reported by other 
African and International studies in a similar population. Hyperpigmentation due to HAART 
accounted for 50% of the intra-oral lesions detected. Other intra-oral lesions included focal 
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epithelial hyperplasia, major aphthous ulcer, recurrent herpetic infection and ulcer of unknown 
origin. Ten children presented with extra-oral lesions and 80% of these lesions were caused by 
diseases related to the Herpesviridae family. We report no significant association between 
presence of lesions and CD4
+ 
T-lymphocyte count, viral load, age at diagnosis, duration of 
HAART and HAART regimen. However, a significant statistical association was found between 
presence of oral lesions and current age. The average current age of children presenting with oral 
lesions is 10,7 years. Six children out of 22 presenting with oral lesions, presented with 
discordant responses to HAART. 
 
Conclusion 
 
The prevalence of oral lesions in paediatric patients on HAART in this cohort was low. The 
significant association of current age and the presence of lesions may reflect the evolution of 
prevention of mother to child transmission strategies and more timely diagnosis of HIV and 
HAART implementation over the last ten years. However, further research needs to be 
conducted into discordant responses to HAART in the paediatric population. 
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DEFINITIONS 
 
HAART is defined as a combination of ARV drugs; usually two nucleoside reverse transcriptase  
inhibitors and a protease inhibitor or one nucleoside reverse transcriptase inhibitor, a non- 
nucleoside reverse transcriptase inhibitor and a protease inhibitor (11). 
 
Initiation of HAART is defined as the first time three or more antiretroviral drugs from at least  
two different classes are administered within one week (27). 
 
Disease progression is defined as a more advanced disease stage after baseline evaluation (35). 
 
Clinical failure is defined as the appearance or reappearance of WHO clinical stage 3 or stage 4  
events after at least 24 weeks on ART in a treatment- adherent child (94). 
 
Immunologic success is defined as an increase from pre- ART CD4
+ 
T-lymphocyte count or an  
increase in CD4
+ 
T-lymphocyte percentage ≥ 15% (95). 
 
Immunologic failure is defined as developing or returning to the following age-related  
immunological thresholds after at least 24 weeks on ART, in a treatment-adherent child: (1)  
CD4
+ 
T-lymphocyte count of< 200 cells/µl or percent CD4+ < 10% for a child two years and  
older but less than five years of age. (2) CD4
+ 
T-lymphocyte count < 100 cells/µl for a child 5  
years of age or older (94). 
 
Virologic success is defined as achieving a viral load < 50 copies/ml (95). 
 
Virologic failure is defined as a persistent HIV viral load ≥ 5000 copies/ml after at least 24  
weeks on ART in a treatment-adherent child (94). 
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CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
1.1Introduction 
 
The human immunodeficiency virus (HIV) has had a global impact with an estimated 3, 4  
million children living with HIV at the end of 2011. Ninety one percent of these children live in  
sub-Saharan Africa (1). The Acquired Immunodeficiency Syndrome (AIDS) is the cause of one  
third of deaths in children under the age of five (2). 
 
The majority of children in developing countries are born into extreme poverty and this is the  
major challenge to paediatric HIV care. The long history of economic migration in Africa or in  
the case of orphans with the death of one or both parents, likely due to HIV, means that  
caregiving roles are often adopted by those other than the biological parents, mainly  
grandmothers and aunts (3). With the increased responsibility of caring for additional children in  
the household arise a number of financial, social and educational challenges (4). Adoptive  
caregivers who may have their own HIV illness, are often elderly and suffering from chronic  
diseases themselves and are unable to provide proper care to the HIV-positive (HIV+) child.  
Extended family caregiving is not always feasible, and many children leave school to head  
households. Furthermore, the stigma related to HIV+ patients and even those who are related to  
or care for an HIV+ patient, known as secondary stigma (4), presents as a psychosocial  
impediment to timely HIV diagnosis and/or treatment in the paediatric population. 
 
Vertically acquired HIV infection, that is mother to child transmission, accounts for 85% of all  
paediatric cases worldwide (5).Vertically infected children are different from infected adults as  
they have immature immune systems and thus the virus has a shorter incubation period with a  
more rapid and fulminant disease process (6, 7, 8, 9, 10, 11).The HIV disease course in children  
has many similarities to that in adults, however, differences in risk factors, modes of  
transmission, patterns of seroconversion and natural history exist. The spectrum of clinical  
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lesions found in the HIV+ paediatric population is another considerable difference. The oral  
cavity is home to numerous fungal, bacterial and viral microorganisms and is particularly  
susceptible to infection in HIV+ patients (5). Oral manifestations of HIV/AIDS present as  
important clinical signs of immunosuppression, HIV viral load and disease progression (12). The  
prevalence of oral lesions in HIV+ paediatric patients varies in different parts of the world, with  
figures as high as 63% reported in South African children (5). This is in comparison to 61%  
prevalence rate in Brazil, 55% in Romania and 49% in Thailand (13). 
 
Through quantitative and qualitative restoration of the immune response, highly active  
antiretroviral therapy (HAART), has altered and decreased morbidity and mortality of HIV- 
infected individuals (14). Majority of children achieve immune reconstitution and virologic  
control, however there are a subset of individuals who clinically worsen with recovery of the  
immune system, which leads to a new spectrum of diseases. This is called the Immune  
Reconstitution Inflammatory Syndrome (IRIS) (15). 
 
There is an abundance of literature on oral lesions in HIV+ adults but there are comparatively  
few reports on children, particularly in South Africa (5,12).The significance of this study is  
that oral lesions in children on HAART, may be clinical predictors of HAART failure or disease  
syndromes related to HAART. Identification of these lesions is important for both medical and  
dental practitioners to administer the correct multidisciplinary approach to paediatric HIV care.  
Therefore, the aim of this study is to profile and characterize oral lesions in paediatric patients on  
HAART. Objectives include describing the types of clinical oral lesions found in children on  
HAART ; to assess if CD4+ T-lymphocyte count, viral load and HAART regimens are  
determinants for the types of lesions found; to report on cases of the immune reconstitution  
inflammatory syndrome and to compare the findings of this study to other South African,  
African and international studies in a similar population.  
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1.2 Literature review 
 
South Africa is home to the world’s largest HIV epidemic, with 6,3 million HIV-infected  
individuals in 2013 (16).According to the UNAIDS HIV and AIDS estimates, 360 000  
children, aged between 0 and 14 years were living with HIV/AIDS in South Africa in 2013. Two  
million and four hundred thousand children, between 0 to 17 years of age, were orphaned by the  
AIDS pandemic (16).The high coverage of efficient prevention of mother to child  
transmission (PMTCT) interventions has resulted in a substantial reduction in new paediatric  
HIV infections at 6 weeks of age from 5.8% in 2009 to 3.5% in 2010 and 2.7% in 2011.  
However, this still translates into thousands of infants infected annually (17). 
 
Chronic pneumonitis, otitis media (including other recurrent bacterial infections), chronic  
diarrhea, lymphadenopathy, hepatosplenomegaly, developmental delays and failure to thrive are  
the major systemic symptoms in paediatric HIV (5). However, oral lesions are often the first  
symptoms of HIV infection with oral candidiasis being the most common manifestation in this  
population (5,6,7,8,9,12,18,19,20,21,22). 
 
Antiretroviral therapy (ART) is the treatment indicated for HIV- infected individuals as it  
successfully suppresses replication of retroviruses and brings about preservation of the immune  
system. The first antiretroviral treatment was advocated as a single drug therapy. However, it  
was found that due to the mutative potential of the virus, improvements in clinical and  
immunologic status of patients were not sustained and resistance to monotherapy followed.  
This led to the advent of combination therapy with the use of at least 3 drugs from two different  
classes of drugs for treatment of the HIV infection. This is called highly active antiretroviral  
therapy (11). Currently, antiretroviral therapy consists of 30 different drugs from 8 different  
categories including nucleoside and nucleotide reverse transcriptase inhibitors (NRTI), non- 
nucleoside reverse transcriptase inhibitors (NNRTI), protease inhibitors (PI), entry inhibitors  
(fusion inhibitors), HIV integrase inhibitors, co-receptor antagonists (also known as CCR5  
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antagonists) and maturation inhibitors (11).  
 
The mechanism of action of a nucleoside reverse transcriptase inhibitors (NRTI) is through its  
incorporation into the newly synthesized viral DNA strand and to act as a ‘faulty nucleotide,’  
resulting in DNA chain termination. Non-nucleoside reverse transcriptase inhibitors (NNRTI)  
bind directly to the enzyme called reverse transcriptase and interfere with its function.  
Protease inhibitors (PI) target the activity of the enzyme called protease and inhibits the final  
assembly of new virions (11). 
 
Based on the World Health Organisation (WHO) protocol, the current regimen of HAART in  
South Africa and that which is advocated at the Rahima Moosa Mother and Child Hospital in  
Johannesburg, for patients under the age of 3 is: Abacavir (NRTI) + Lamuvidine (NRTI) +  
Kaletra syrup (Lopinavir/Ritonavir, which are PIs). Paediatric patients over the age of 3 receive:  
Abacavir (NRTI) + Lamuvidine (NRTI) and Efavirenz (NNRTIs).  This regimen follows the  
protocol of standardized national ART regimens for infant and children as directed by the South  
African Department of Health (23).  
 
In resource-poor countries such as those in sub-Saharan Africa, providing HIV care to infected  
patients is challenged with regards to laboratory monitoring. The benefit of antiretroviral therapy  
may be dampened by long term toxicity and the emergence of drug resistant virus. Routine  
monitoring of HIV viral load and CD4
+ 
T-lymphocyte count allows for detection of side effects  
of medications and drug resistant virus. The WHO recommends monitoring CD4
+ 
T-lymphocyte  
count every six months and viral load testing when the capacity exists. However, in developing  
countries, cost of laboratory monitoring compounded by the lack of technical expertise and  
infrastructure means that routine monitoring may not always be feasible. This means that patients  
may experience prolonged virologic failure and develop drug resistant mutations without  
detection, which could increase morbidity and mortality (24). After the scaling up of ART  
programs, the South African National Health Laboratory Service (NHLS) responded by  
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providing an increased number of laboratories for HIV viral load and CD4 testing services.  
However, with the increasing numbers of patients eligible for ART, additional capacity of the  
existing laboratory services is required (25). Hsiao et al, studied the linkage of South African  
infants from HIV diagnosis to ART services and reported that linkage to care is more likely in  
children in urban areas than in rural areas (Odds ratio (OR) =1.89, 95% CI). The explanation for  
this in part is mothers not returning to receive results due to the migration patterns of women 
 during pregnancy and postpartum. Women in South Africa are known to migrate to urban 
centres for antenatal care (ANC) and maternal care but return to rural areas after giving  
birth (26). In these areas, a further delay is caused by difficulties experienced in conducting HIV  
testing at primary health care centres, transporting specimens to the laboratories and the return of  
results back to the centre. This delay may necessitate referral of the infant to another centre,   
which may increase mortality in this population (26). Furthermore, Glencross et al, reported that  
most clinics in South Africa have reasonable access to laboratory services. However, they  
acknowledge that resources are limited in South Africa and a geographical difference in  
distribution of services exists, with the focus of service being on more densely populated areas.  
West and North West areas of the country were found to have general pathology services but  
lacked CD4 testing facilities. The study confirmed that patients requiring CD4
+
 tests from these  
areas had to be referred to adjacent districts sometimes 100-200 km away; which may cause  
delay in treatment (25). In the study by Glencross et al, the national laboratory service was  
deemed largely reliable, however, site visits to provincial clinics revealed that many clinics are  
challenged by regional transport and logistical deficiencies, staffing and skills deficiencies and  
poor or inconsistent electricity supply(25). 
 
The response markers such as HIV-1 RNA plasma levels and CD4
+ 
T-lymphocyte count vary 
greatly between adults and children. In children due to the presence of an active thymus gland,  
immune recovery following HAART is stronger than in adults. However, virologic response is  
diminished in comparison to adults this is because in children, particularly in infants, the  
immature immune system allows less efficient control of HIV replication, resulting in high viral  
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loads. The increase in CD4 
+ 
T-lymphocyte count is independent of the rate of virologic response 
(27). 
 
In a study conducted by Walker et al, the authors evaluated the association between age, 
HAART initiation, CD4
+
cell percentage and HIV-1 RNA loads. Within the first few years of life  
in all children, including HIV-uninfected children, there is a natural but considerable decline in  
CD4
+  
T –lymphocyte count. Therefore, in this study, immunologic response was measured in  
CD4
+
 cell percentage instead of CD4
+ 
 T-lymphocyte count. They found that CD4
+
 cell  
percentage increased substantially after HAART initiation regardless of pre- HAART HIV-1  
RNA or the clinical status of the patient. Short and long term increases were greater and faster in  
younger children than in older children, even if they were severely immunosuppressed. Once  
again this may be attributed to an active thymus gland in younger children. In contrast to  
successful immunologic response, younger children are less likely to achieve HIV-1 RNA <400  
copies after initiating HAART (27). This is in agreement with the study conducted by Ramirez-  
Amador et al (14) which suggested that children can restore immune function well without  
complete viral suppression. However, poor virologic response leads to an increased risk of drug  
resistance, which is of concern. Older children showed slower increases in CD4
+ 
% but  
presented with viral loads of HIV-1 RNA< 50 copies/ml. In both younger and older children,  
pre-HAART viral load was not a significant predictor of virologic response. Therefore,  
children of the same age, with high pre-HAART viral loads have the same chance of viral  
suppression as those with lower viral loads. This is in contrast to studies conducted in adults,  
which show that patients with lower pre-HAART HIV-1 RNA have a better chance of  
achieving undetectable values (27). 
 
A relationship between the virologic response and the plasma drug concentration exists.  
Inadequate plasma concentrations of, in particular, protease inhibitors, may be accountable for  
the differences in virologic response rates (14). In South Africa, children ˂ 3 years of age, are  
prescribed regimens that include PI’s. As reported by van Zyl et al, Lopinavir (LPV), co- 
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formulated with low dose Ritonavir (LPV/r) is the preferred drug of choice as it has a high  
resistance barrier. Furthermore, many infants in the South African situation are co-infected with  
tuberculosis and require Rifampin therapy. Rifampin reduces the metabolism of LPV and  
reduces plasma concentration. Ritonavir (RTV)-only PI’s have been found to be independently  
associated with major PI resistance and mutations. Therefore combination LPV/r at correct  
dosages is used in our protocols (28).Furthermore, a study conducted by Meyers et al, reports 
that Rifampin therapy is common in the South African setting as many children are co-infected  
with TB. They report that Rifampin causes accelerated clearance of both PI’s and NNRTI’s and  
therefore reduces plasma concentrations (29).  Walker et al, found that children who received  
lower than recommended doses had a lower chance of suppressing viral load. They found that  
under-dosed children were able to suppress viral loads to HIV-1 RNA  < 400 copies/ml but not to  
HIV-1 RNA < 50 copies/ml. However, dosing had no effect on the immunologic response (27). 
This is further supported by a study conducted in South African children by Orrell et al, who  
reported that poor adherence or adherence to a suboptimal regimen or dosing can lead to first and  
second line treatment failure (30). ABC and 3TC currently form part of the first line of treatment  
under the South African National ART guidelines. These guidelines followed WHO  
recommendations in 2010 to replace d4T with ABC as there were growing concerns related to  
d4T toxicity. A study conducted by Technau et al, reported that children treated with ABC/3TC  
have a lower chance of achieving viral suppression and a higher chance of viral rebound than  
children treated with d4T/3TC combinations. Therefore concerns about viral failure related to  
NRTI’S also exists and is not only related to PI’s (31). The difficulty faced in administering  
HAART to paediatric patients is lack of paediatric formulations, limited options of drugs  
available for children, reliance on caregivers to administer the medication and toxicity of  
HAART in long term therapy (14,31). Early initiation of HAART for children decreases  
mortality and disease progression. It is important that timely initiation of HAART occurs and an  
attempt is made to balance progression of HIV disease, complicated long term side effects and  
development of resistance (17). Furthermore, in the South African setting where treatment  
options are limited and the potential toxicity associated with lifelong ART is a reality, Cotton et  
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al, investigated the outcomes of early time-limited ART and deferred ART, in the children with  
HIV early antiretroviral treatment (CHER) trial (32).The concept of early time-limited ART,  
which is initiated at diagnosis of primary infection, is to prevent disease progression but also  
safely allow a subsequent planned period off ART,  thus reducing resistance and preserving  
future treatment options. The results of this trial found that early time-limited ART had better  
clinical outcomes than deferring ART to a later age as an attempt  to prevent long term toxicity  
or drug resistance. The reason for this may be in part due to the fact that initiating ART early  
limits the HIV reservoir and preserves the immune response (32). 
 
Eligibility for ART initiation as guided by the South African Department of Health is as follows 
(23): 
 
Table 1.2.1 Criteria for eligibility to start ART (23) 
 
Eligible to Start ART 
 
 All children less than 5 years of age, irrespective of CD4+ T-lymphocyte count. 
 
 Children 5-15 years of age with WHO clinical stage 3 or 4 of CD4+ T-lymphocyte 
count ≤ 350 µl 
 
 
Require Fast-Track (start ART within 7 days of being eligible) 
 
 Children less than 1 year of age 
 
 WHO clinical stage 4 
 
 MDR or XDR-TB 
 
 CD4+ T-lymphocyte count <200 cells/µl 
 
 
 
Current WHO recommendations include initiation of HAART to all children younger than 12-24  
months regardless of the CD4
+ 
 T- lymphocyte count or viral load (23). WHO antiretroviral  
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guidelines are updated every two years. The above mentioned protocol is adopted from the 2013  
consolidated guidelines, which were supplemented in March 2014. The latest guidelines  
recommend ART to be initiated for all patients with CD4
+ 
T-lymphocyte counts ≤ 500  
cells/mm
3
. The guidelines also state that it should be initiated immediately, regardless of CD4
+  
T-lymphocyte count, in children up to the age of five years, individuals with active tuberculosis,  
individuals co-infected with HBV with severe chronic liver disease and individuals living in  
sero-discordant partnerships. All pregnant and breast feeding women should be offered lifelong  
ART (33).The 2013 guidelines raised the threshold to 500 cells/mm
3
, thus attempting to  
accelerate the trend of early initiation. Speculations of future 2015 guidelines may be  
administration of ART to all patients , regardless of CD4
+ 
T-lymphocyte counts as is  
recommended in developed countries such as France and the United States of America. This is  
not true for all developed countries as the most recent United Kingdom guidelines still  
recommend starting ART ≤ 350 cells/mm3 and to only “ consider” initiating ART ≤ 500  
cells/mm
3 
(34).Children who initiate HAART at a time of mild disease are reported to show 
reduced progression to moderate disease. When progression does occur it is delayed by 3 years 
(35). HAART use in children with moderate disease at initiation is associated with a decreased  
proportion of children progressing to severe disease and death. Therefore, HAART, is associated  
with reduced and delayed progression of HIV regardless of the disease stage at initiation.  
Furthermore, for children who show progression it is primarily based on laboratory  
immunosuppression rather than clinical disease (35). 
 
It can therefore be concluded that immune recovery occurs rapidly in HIV-infected children  
after the initiation of antiretroviral therapy and majority of children benefit greatly from therapy.  
However, perinatal transmission of HIV is often associated with neglected HIV  
prevention measures and so there is a delay in diagnosis and thus a delay in initiation of  
treatment. 
 
Studies conducted by Egger et al, suggested that CD4
+ 
T-lymphocyte counts, in particular,  
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baseline CD4
+ 
T-lymphocyte count is more strongly associated with the probability of disease  
progression to AIDS or death in patients on HAART. They concluded from their findings that  
baseline viral load does play a role in disease progression but only in individuals with baseline  
viral loads above 100 000 copies/ml (36). Furthermore, Helleberg et al observed that  
CD4
+ 
T-lymphocyte count is also a marker of inflammation or unstable atherosclerotic plaques.  
In this study, it was also shown that in the absence of immunosuppressive drugs, radiotherapy  
and chemotherapy, virally-suppressed patients showed a considerable drop in CD4
+ 
T- 
lymphocyte count and this was associated with an increased risk of death, emphasizing the  
importance of regular monitoring of CD4
+ 
T-lymphocyte counts in patients receiving ART  
(37). These findings were further supported by a study conducted by Lapadula et al, who  
reported that patients who showed a positive virologic response to treatment coupled to  
immunologic failure, had a higher risk of progression to AIDS. Furthermore, the inability of the  
immune system to detect and destroy neoplastic cells, compounded by persistent immune 
 activation also influences the risk of developing non-AIDS malignancies and cardiovascular  
disease. Hence, the authors suggested monitoring CD4
+ 
T-lymphocyte counts every 6 months  
even after achieving viral suppression. The findings of this study also support the protocol to  
administer ART to patients with CD4
+ 
T-lymphocyte counts ≤ 500 cells/mm3 as mortality  
amongst patients with CD4
+ 
T-lymphocyte> 500 cells/mm
3
 with prolonged viral suppression is  
the same as that of the general population (38). Despite these findings, protocols developed by  
the Office of AIDS Research Advisory Council (OARAC), which were updated in May 2014,  
state that measurements of CD4
+ 
T-lymphocyte counts is useful prior to ART initiation and viral  
load should be used to monitor the effectiveness of therapy after initiation. The viral load is the  
established surrogate marker for treatment response (39). These guidelines have taken lead from  
much prior studies conducted by Mellors et al, who concluded that viral loads strongly predict  
that rate of decrease in CD4
+ 
T-lymphocytes and the progression to AIDS and death. However,  
women, children and members of different ethnicities and racial minority groups were not  
included in this study (40). The OARAC protocol states that CD4
+ 
T-lymphocyte count  
monitoring has no clinical benefits in virally-suppressed patients who have CD4
+ 
T-lymphocyte  
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≥ 200 cells/mm3 after 48 weeks on therapy (39). This is supported by more recent studies  
conducted by Girard et al, who agree that there is little clinical benefit in continued CD4
+ 
T- 
lymphocyte count monitoring in patients who have viral loads ≤ 50 copies/ml and CD4+ T- 
lymphocyte counts ≥ 200 cells/mm3 (41).It states that although a decline in CD4+ T-lymphocyte  
count may occur in patients with successful viral suppression, it is uncommon. Furthermore, the  
costs of monitoring CD4
+ 
T-lymphocyte counts from 6 months to 12 months will result in a  
significant amount of annual savings. However, patients who fail to maintain viral suppression  
whilst receiving treatment, should be monitored for CD4
+ 
T-lymphocyte counts every 3 to 6  
months (39). It has been well established that disease progression is marked by a decrease in the  
laboratory marker of CD4
+ 
T-lymphocyte count and an increase in plasma viral load. However,  
in developing countries, the tools and/or resources to consistently monitor progression of disease  
may not be available. Therefore, clinicians rely more on clinical parameters such as weight and  
height to monitor progress, particularly in the paediatric HIV+ population (42).  
 
Weight and height of HIV+ paediatric patients tends to lag behind HIV-uninfected children of  
the same age (43). Growth failure, which is not only in the form of stunting and weight loss but  
also failure to thrive, is attributed to inadequate calorie intake, gastrointestinal infections,  
opportunistic infections and endocrine abnormalities (40). HAART results in improvement in  
weight-for-age and height-for-age in comparison to baseline values. Increases in weight and  
height are seen in patients who are viral responders more significantly than non-responders and  
therefore successful HAART should have a positive impact on growth (43). There are, however,  
studies conducted by Yotebieng et al, that found antiretroviral treatment to be associated with  
improved weight-for-age and height-for-age but not associated to viral suppression or treatment  
failure (44). In a study conducted by Musoke et al, it was found that children who were on  
HAART but not showing a significant increase in weight or height were also experiencing  
immunologic failure (45). Therefore, these basic growth parameters, which are inexpensive to  
measure by primary health care workers in resource-limited settings, are associated with  
successful HIV treatment outcomes and form good predictors of clinical disease progression and  
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are useful markers for high –risk children (45). Paediatric HIV+ patients are routinely monitored  
for height and weight in follow up appointments because poor nutritional status and stunting at  
the time of ART initiation is associated with a poor prognosis (44). Furthermore, other studies  
have confirmed that low CD4
+ 
T-lymphocyte counts, anemia, chronic diarrhea, reduced  
weight-for-age and WHO clinical stage 4 conditions at the time of ART initiation contribute  
significantly to paediatric mortality and disease progressions, despite treatment with ART (46). 
 
Anemia is defined as having a haemoglobin level ≤ 10 mg/dl (47). Severe anemia is defined as  
having a haemoglobin level ≤ 6,5mg/dl (42). Studies conducted by Koye et al, found low  
haemoglobin levels at initiation of ART to be a significant predictor of mortality in children on  
treatment. Furthermore, it is commonly associated with disease progression and death in  
paediatric patients with HIV(47). Children with lower CD4
+ 
T-lymphocyte counts at initiation  
are at a greater risk of opportunistic infections, which can impair the positive effects of  
ART. Chronic diarrhea decreases drug absorption and impairs metabolism (48). The WHO has  
four clinical stages to represent the clinical forms of disease in patients not receiving treatment.  
Stage 4 is advanced HIV/AIDS disease. Clinical staging allows children at risk of rapid disease  
progression to be recognized and in severely limited settings, it allows resources to the  
prioritized to patients that need them the most (49).  
 
Oral manifestations of HIV in children are classified according to the European Community – 
Clearinghouse (EC-Clearinghouse) and WHO. Existing diagnostic criteria have been updated by  
the Oral HIV/AIDS Research Alliance (OHARA)(50). 
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Table 1.2.2 OHARA oral manifestations of paediatric HIV (50) 
Fungal Viral Bacterial Salivary 
gland disease 
Neoplasms Idiopathic 
 
Pseudomembranous 
Candidiasis 
 
 
Hairy 
leukoplakia 
 
Necrotizing 
gingivitis/ 
periodontitis 
 
Parotid 
enlargement 
 
Oral Kaposi 
Sarcoma 
 
Recurrent 
aphthous 
stomatitis 
 
 
Angular cheilitis 
 
Herpes 
labialis 
 
  
Salivary 
hypofunction 
 
Oral non-
Hodgkins 
lymphoma 
 
 
Ulcerations 
  
Recurrent 
intra-oral 
herpes 
simplex 
 
   
Oral 
squamous 
cell 
carcinoma 
 
Necrotizing 
stomatitis 
 Oral Warts 
 
    
 
IRIS, also known as the immune reconstitution syndrome or restoration disease (14), is defined  
as a collection of signs and symptoms resulting from the ability to mount an immune response to  
antigens or organisms, associated with immune recovery, that is, an increase in CD4
 + 
 T- 
lymphocyte count and/or a rapid decrease in viral load, in patients on antiretroviral therapy (52). 
Immune reconstitution is defined as a CD4
+ 
T- lymphocyte cell count of >200 cells/mm3 or an  
increase of ≥100 cells/mm3 over baseline any time since the initiation of HAART (53). It is a  
consequence of antigen-specific exaggerated inflammatory response in which the normal  
regulatory mechanisms, that limit the degree of inflammation, are absent (14). 
 
There are two clinical syndromes associated with IRIS; the “unmasking” and the  
“paradoxical” syndromes. In unmasking IRIS, there is a subclinical, previously unrecognized  
infection which flares up after HAART initiation. Paradoxical IRIS is the exacerbation of a  
past known and often treated disease (9). A third syndrome of IRIS possibly exists. In addition to  
the paradoxical and unmasking syndromes, an autoimmune syndrome is also thought to exist.  
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This is not a well studied phenomenon but has been seen with regards to Hashimoto’s thyroiditis.  
Further research still needs to be conducted for this syndrome to be officiated (54). 
French also reported autoimmune diseases in HIV+ patients who responded favourably to  
antiretroviral treatment. He reported evidence on Graves disease as a complication of immune 
restoration seen in patients who recovered from severe CD4
+  
T-lymphocyte deficiency (55). 
This was supported by Dhasmana et al, who reported that Graves disease has a tendency to occur  
approximately two years after ART initiation (56). Although the aetiology of this possible third  
syndrome of IRIS has not yet been identified; it may be due to an increased susceptibility to  
autoimmune diseases as a result of an acquired defect in immune tolerance (55). Sarcoidosis has  
also been reported to be a potential autoimmune disease related to the restoration of the immune  
system(55). The manifestations of re-occurrence of sarcoidosis include lymphadenopathy,  
pulmonary involvement, erythema nodosum and other skin eruptions (56). 
 
Currently, there are no confirmatory tests for IRIS and it remains a diagnosis of exclusion (51).  
IRIS is considered in patients who have an emergence or clinical worsening of opportunistic  
infections. These conditions may occur with an unusual presentation or disease course wherein 
the possibility of HAART failure and adverse drug reactions have been excluded. The  
appearance of symptoms has a temporal relationship with the initiation of  therapy and associated  
immune recovery (52). Ramirez-Amador et al, concurred with this statement and described IRIS  
as a rapid, dysregulated restoration of antigen-specific immune response during antiretroviral  
therapy that most often occurs within 3 months of therapy initiation (14). 
 
The pathogenesis of IRIS is not well understood. HIV infection depletes CD4
+ 
T lymphocyte  
cells including  T-helper cells 1 (TH1) and regulatory T-cells (TREGS).  TH1 cells mediate the  
predominant host defense against extracellular pathogens and TREGS are responsible for  
immunoregulation. Following initiation of HAART, there is a rapid recovery of TH1 and a  
slower reconstitution of  TREGS.  IRIS may be attributed to an exaggerated, uncontrolled  
inflammatory immune response due to TH1 cells in the absence or deficiency of normal T-cell  
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regulatory mechanisms. Furthermore, there has been a discovery of a new lineage of T-helper  
cells called T-helper 17 cells (TH17). The T-helper 17 plays a critical role in maintaining  
inflammatory response and is known to produce an accelerated memory response to antigens.  
TREGS and TH17 have a reciprocal relationship and in the absence of TREGS, the restoration of  
TH17 may further contribute to the cytokine imbalance in favour of pro-inflammatory signals 
 (14). 
 
A review done by dos Santos Pinheiro et al, reported a reduction in the frequency and  
severity of HIV associated oral disease after using HAART (57). However, they also found an  
association between treatment with HAART and increased presentation of salivary gland  
disease and oral warts caused by the Human Papilloma Virus (HPV) in children. However, this  
study conducted by dos Santos Pinheiro et al, was a study based on a literature review. This  
means that direct comparisons between the studies cannot be made to obtain concluding results  
as each study viewed had different subject groups and methodologies. Furthermore, case-control  
studies were also included in the literature search and it is difficult, once again, to base  
conclusions on single case-study reports. The prevalence of oral diseases such as oral  
candidiasis (OC), Kaposi Sarcoma (KS) and oral hairy leukoplakia (OHL) have decreased since  
the introduction of HAART. However, conditions such as oral hyperpigmentation was  
significantly increased in the paediatric population receiving HAART (57). A study conducted  
by Wang et al, found Herpes viruses to be commonly associated with IRIS in both adults and  
children, with the varicella zoster virus (VZV) and herpes simplex labialis virus occurring most  
commonly in children (15). Various studies have reported different prevalence rates of IRIS in  
the paediatric population. Studies in Thailand, India and Peru have reported prevalence rates of  
18,9%, 19% and 20% respectively (15,52). Studies conducted by Boulware et al, reported an  
incidence rate of 10-19% (51).  However, little is known about oral lesions in paediatric patients  
on HAART and the incidence of IRIS with most studies concluding that further research should  
be conducted in this field. 
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CHAPTER 2: METHODS 
 
2.1 Study design and population 
 
The study was a cross-sectional, descriptive investigation. It was conducted on HIV+  
paediatric patients attending the Empilweni Clinic, at the Rahima Moosa Mother and Child  
Hospital, Johannesburg, Gauteng, South Africa from March 2014 to April 2014. The WHO  
classifies age groups as neonates (less than one month old), infants (one years old or younger but  
older than one month), children (older than 1 years but under the age of ten), adolescents  
(individuals between the ages of ten and nineteen) and adults ( nineteen years and older) (1). 
 
2.1.1 Inclusion criteria 
 
Paediatric patients with a confirmed HIV
+ 
status, CD4
+  
T- lymphocyte cell counts and viral  
loads, aged between one month -14 years old. All patients are on HAART. 
 
2.1.2 Exclusion criteria 
 
Children not on HAART, outside of the age group (neonates) or those with incomplete records  
such as missing CD4
+
  T-lymphocyte counts and viral loads, were not included in the study. 
 
This was a convenient sample as, due to ethical reasons, it is difficult to determine the HIV  
status of children in a general population. 
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2.2  Ethical considerations 
Ethical approval (Appendix A) for this study was obtained from the Committee for Research in 
Human Subjects at the University of the Witwatersrand. The clearance certificate number is 
M131045. Information on the study was made available in two languages, English and Zulu, to 
the patients’ parents, guardians and caregivers as applicable, after which informed consent was 
sought.Informed consent (Appendix B) was attained from the patients’ parents, guardians or 
caregivers before examinations commenced. Consent was obtained for clinical examinations and 
any photographs to be taken. Informed consent forms were made available in two languages, 
English and Zulu. Children over the age of 7 years signed a minor assent form (Appendix C). 
 
2.3  Clinical Examination 
A total of 240 HIV infected children, aged 1 month to 14 years, of which 128 were male and  
112 were female, were examined at the Empilweni Clinic between March 2014 and April 2014.  
The classification for presumptive diagnostic criteria for oral lesions was based on the review of  
Oral HIV/AIDS Research Alliance: updated case definitions of oral disease endpoints (18). The  
examinations were conducted by the investigator, who was calibrated prior to commencement of  
clinical examinations, according to the case definitions mentioned above. Calibration was done  
by diagnosis of 34 clinical photographs of oral lesions under test circumstances. The test was  
repeated twice thereafter, at intervals 1 day and 3 days until 90% accuracy was achieved.  
Unfortunately, intra-examiner calibration could not be ensured by re-examining a small  
percentage of children due to the unwillingness of parents and caretakers to take time off work to  
bring the children to the clinic for a non-medical all-research purpose examination. Children at  
the Empilweni clinic are seen on a monthly basis, as this study was completed in a month no  
child was examined twice. Returning for re-examination would mean parents/ caregivers have to  
take a day off work and children miss a day of school. Furthermore, an extra trip to the clinic  
incurs additional transport cost. For similar reasons on telephonic follow- up with parents, no  
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children clinically diagnosed with oral lesions presented for biopsy of lesions. Therefore, re-  
examinations and biopsies of lesions could not be performed and serves as a limitation for this  
study. 
 
Oral examinations were conducted with children sitting on a chair or on the lap of a caregiver.  
Examinations consisted of palpation and visual inspection of the mouth and facial structures,  
using a wooden spatula and hand-held light. If a lesion was detected and required biopsy and   
treatment, the patient was referred to the Department of Oral Medicine and Periodontology at  
the University of the Witwatersrand. A letter was also written and placed in the file to inform  
the medical practitioner of the presence of the oral lesion, suggesting blood tests to check CD 4
+  
T-lymphocyte counts and viral loads, to be repeated if deemed necessary. Blood tests were  
recommended in all patients presenting with oral lesions excluding hyperpigmentation due to  
HAART therapy. Photographs of the lesion were taken, without revealing the identity of the  
patient. These were used to facilitate profiling and characterization of lesions, but also as an aide  
for quality/accuracy control. Photographs were used as aides in accuracy control by visually  
comparing diagnoses made by the examiner with that of an experienced clinician. No  
discrepancy was detected during comparison, and a 100% agreement on diagnoses was recorded.  
Informed consent was obtained prior to taking photographs. Age (in months and years) currently  
and at the time of diagnosis of HIV, duration of antiretroviral treatment (months), viral load  
(RNH-HIV-1 per ml) and CD4
+
 T-lymphocyte cell count (cells/mm3) were recorded from the  
patient’s records following examination.  
 
2.4  Data Analysis 
 
Data was transferred from the data collection sheets onto an Excel
©
 spread sheet and then 
imported into the statistical software, Statistical Package for the Social Sciences (SPSS). 
Descriptive statistics with the use of case processing summary tables and cross tabulations for 
gender was used. Significance of association between age, CD4+ T-lymphocyte count currently 
33 
 
and at baseline, viral load currently and at baseline and duration of HAART with the presence of 
oral lesions was determined using t-tests. A P- value <0.05 was considered significant. Given the 
skewed distribution of the data and the unbalanced samples of the two groups we were 
comparing, we could not assume normality of the underlying sampling distributions. Therefore 
we had to revert to conducting non-parametric, Mann Whitney tests and not t-tests. Pearsons 
correlation test was used to determine the association between CD4+ T-lymphocyte count and 
viral load.  
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CHAPTER 3: RESULTS 
 
The total sample for this study constituted 240 valid cases made up of 128 males and 112  
females. . Table 3.1 shows the distribution of the sample by lesions group (Yes - positive for  
“have oral lesions” or No – negative for “have oral lesions”). Twenty two out of 240 cases had  
oral lesions (9,2%). 
 
Table 3.1 “Have lesions” 
 n % 
Have lesions Yes 22 9.2% 
No 218 90.8% 
Total 240 100.0% 
 
Of the twenty two cases with oral lesions, 41% were female and 59 % were male (table 3.2). 
 
 
Table 3.2 “Have lesions” by gender 
 
 Gender 
Female Male Total 
Have lesions Yes n 9 13 22 
% 8.0% 10.2% 9.2% 
No n 103 115 218 
% 92.0% 89.8% 90.8% 
Total n 112 128 240 
% 100.0% 100.0% 100.0% 
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Of the lesions detected, ten children presented with extra-oral lesions and twelve children  
 
presented with intra-oral lesions (Table 3.3). HAART-induced hyperpigmentation constituted  
 
majority of the intra-oral lesions detected.  This is a difficult lesion to diagnose and criteria  
 
included asymmetric, localized areas of pigmentation on oral mucosae but more importantly  
 
no reports of pigmentation in the medical history prior to therapy. Other lesions included  
 
focal epithelial hyperplasia, major aphthous ulcer, ulcer of unknown origin and recurrent  
 
herpetic infections. Amongst those presenting with extra-oral lesions, three children  
 
presented with scarring as a result of previous herpes varicella zoster (chicken pox) and one  
 
child presented with active herpes varicella zoster at the time of examination. One child  
 
presented with scarring as a result of herpes zoster. Two children presented with scarring as a  
 
result of previous herpes simplex and one child presented with active herpes simplex at the  
 
time of examination. History obtained from parents/ caregivers confirmed that those children  
 
who presented with scarring were on HAART at the time of active disease. This was  
 
corroborated with the medical history from the files and confirmed by checking treatment  
 
previously administered for the lesions where possible. However, cases where the child was  
 
receiving treatment at another clinic or in a different region of South Africa did occur, as  
 
well as cases where at the time of the lesion, patients did not report to the clinic for treatment  
 
and so there is no record of it in the files. Other extra-oral lesions detected included  
 
molluscum contagiosum and skin eruptions due to hypersensitivity to Bactrim.  No cases of   
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candidiasis, parotid enlargement, Kaposi sarcoma, oral hairy leukoplakia, linear gingival  
 
erythema or cervical lymphadenopathy were found. 
 
Table 3.3 Description of intra-oral and extra-oral lesions 
 
 n % 
Intra oral disease presence: 
Description 
Focal epithelial hyperplasia 3 25.0% 
Hyperpigmentation 6 50.0% 
Major apthous ulcer 1 8.3% 
Recurrent herpetic infections 1 8.3% 
Ulcer of unknown origin 1 8.3% 
Total 12 100.0% 
 
 
 n % 
Extra oral disease presence: 
Description Herpes simplex  3 30.0% 
Herpes varicella zoster 
(chicken pox) 
4 40.0% 
Herpes zoster 1 10.0% 
Hypersensitivity to Bactrim 1 10.0% 
Molluscum contagiosum 1 10.0% 
Total 10 100.0% 
 
 
 
Figure 3.1 illustrates the current age distribution of the sample. An overall average age of 8,7  
years was reported (sd = 3,3). While the distribution of current might not be perfectly normal,  
inspection of the distribution did not reveal any notable outliers. 
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Figure 3.1 Histogram of current age 
 
 
 
Table 3.4 refers to a statistically significant difference in the average current ages of children  
with and without oral lesions group was identified (p = 0,002). Those with oral lesions  
reported an average current age of 10,7 years (sd = 3,4). This in comparison to a lower  
average current age of 8,5 years amongst those without oral lesions (sd = 3,2). 
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Table 3.4 Average current age by lesions group 
 
 Have lesions 
Yes No Total 
Current age Mean 10.7 8.5 8.7 
Standard 
Deviation 
3.4 3.2 3.3 
Median 12.3 8.5 8.8 
Valid n 22 218 240 
 
 
The age distribution at time of HIV diagnosis (refer to figure 3.2) indicates a positively  
skewed distribution. Seventy-eight of the 240 cases (32,5%) were diagnosed with HIV at age  
one and younger, thus during infancy. While an average age of 3,1 years are reported, this  
statistic is skewed by the long positive tail of the distribution. A more representative value  
would therefore be the median age of two years. Therefore this study finds no correlation  
between the age at diagnosis of HIV and the presence of oral lesions. 
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Figure 3.2 Histogram of age at time of HIV diagnosis 
 
 
 
Table 3.5 reports comparative summary statistics for the variable age at time of HIV  
diagnosis by lesions group. For both the average and median values the average age at time  
of HIV diagnosis were observably higher for the Yes-group (4,7 and 3,1) than the No-group  
(3,0 and 2,0). Due to the significantly skewed distribution evident for the dependent variable,  
a Mann-Whitney U test was employed to test whether the two samples of values could be  
considered different. The p-value of 0,080 suggests no significant difference between the Yes  
group and the No group based on the age at time of HIV diagnosis.  
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Table 3.5 Average age at time of HIV diagnosis by lesions group 
 
 Have lesions 
Yes No Total 
Age at time of HIV 
diagnosis 
Mean 4.7 3.0 3.1 
Standard 
Deviation 
4.3 3.0 3.2 
Median 3.1 2.0 2.0 
Valid n 22 217 239 
 
 
The distribution of CD4+ baseline count for the sample group is shown in figure 3.3. The  
distribution reveals a positively skewed tail, indicating the highest frequencies of CD4+  
occuring at lower CD4+ baselines. The median is 651,5 cells per mm
3
 and is reported as a  
more valid measure of central tendency (refer to table 3.6). 
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Figure 3.3 Histogram of CD4+ T-lymphocyte baseline count  
 
Table 3.6 reports the average, standard deviation and median values by lesions group. While  
lower CD4 values are reported for the Yes-group (both the average and median values), the  
p-value of 0,619 from the Mann-Whitney U test suggests no significant difference between  
the Yes-group and the No-group. Therefore there is no significance of baseline CD4
+  
T- 
lymphocyte counts to the presence of oral lesions.  
 
Table 3.6 Average CD4+ T-lymphocyte baseline count by lesions group 
 Have lesions 
Yes No Total 
CD4 baseline 
count 
Mean 756.3 826.7 820.3 
Standard 
Deviation 
669.8 688.1 685.4 
Median 566.5 659.5 651.5 
Valid n 22 218 240 
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The distribution of CD4+ latest count for the sample group is shown in figure 3.4. As in the  
case of the CD4+ baseline count, the distribution reveals a positively skewed tail. The  
average case reported a count of 944 cells per mm
3
 (refer to table 3.7). 
 
Figure 3.4 Histogram of CD4+ T-lymphocyte latest count 
 
 
 
Table 3.7 reports the average, standard deviation and median values by lesions group. Lower  
CD4 values are reported for the Yes-group (both the average and median values), however,  
the p-value of 0,096 from the Mann-Whitney U test suggests no significant difference  
between the Yes-group and the No-group.  Therefore, CD4
+ 
T-lymphocyte count in this study  
did not prove to be a predictor for oral lesions or have any association with the presence of oral  
lesions. 
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Table 3.7 Average CD4+ T-lymphocyte latest count by lesions group 
 Have lesions 
Yes No Total 
CD4 latest 
count 
Mean 888.1 1 060.3 1 045.1 
Standard 
Deviation 
587.7 579.2 580.7 
Median 779.0 971.0 944.0 
Valid n 21 218 239 
 
Figure 3.5 shows the distribution of viral load baseline count for the sample group. The  
distribution reveals a positively skewed tail. A median viral load baseline count of 49 416,5 
copies/ml is reported (refer to table 3.8). 
 
Figure 3.5 Histogram of viral load baseline count 
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The Mann-Whitney U test (p = 0.272) indicates no significant difference between the Yes-  
and No-groups for viral load baseline counts. 
 
Table 3.8 Average viral load baseline count by lesions group 
 
 Have lesions 
Yes No Total 
Viral load baseline 
count 
Mean 278 
144.6 
328 
401.1 
323 
594.0 
Standard 
Deviation 
344 
050.3 
669 
112.0 
644 
805.2 
Median 100 
000.0 
41 514.5 49 416.5 
Valid n 22 208 230 
 
Figure 3.6 shows the distribution of viral load latest count. The distribution reveals a  
positively skewed tail. A median viral load baseline count of 294 copies/ml is reported (refer  
to table 3.9). 
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Figure 3.6 Histogram of viral load latest count 
 
The Mann-Whitney U test reveals a p-value of 0.052. While this suggests no significant  
difference between the Yes- and No-group group for viral load latest counts based on a 95%  
level of confidence, it is only marginally higher than the 0,05 level. 
 
Table 3.9 Average viral load latest count by lesions group 
 Have lesions 
Yes No Total 
Viral load latest 
count 
Mean 14 497.1 14 345.8 14 360.0 
Standard 
Deviation 
37 595.4 98 396.8 94 304.3 
Median 1 148.0 288.0 294.0 
Valid n 19 183 202 
 
 
Inspection of the distribution of number of days on HAART reveals a significant proportion  
of cases (30 cases) that were on HAART for less than 250 days (refer to figure 3.7). 
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Figure 3.7 Histogram of days on HAART 
 
 
The average case have been on HAART for 1 444,5 days. No significant difference was  
evident between the lesion groups (p = 0,533) (refer to table 3.10). 
 
Table 3.10 Average days on HAART by lesions group 
 Have lesions 
Yes No Total 
Duration 
HAART 
Mean 1 599.4 1 474.9 1 485.5 
Standard 
Deviation 
1 002.3 931.0 935.7 
Median 1 583.5 1 435.5 1 444.5 
Valid n 20 216 236 
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While the Spearman correlation between CD4 latest count and viral load latest count  
indicates a negative coefficient of -0,106, the coefficient is, however, not considered  
significantly different from zero (p = 0,132). Therefore no linear relationship exists between  
the two variables. 
Table 3.11 HAART Regimen by lesions group 
 
 
Have lesions 
Yes No Total 
HAART regimen ABC 3TC KALETRA n 11 26 37 
% 50.0% 11.9% 15.4% 
AZT ALLUVIA n 1 0 1 
% 4.5% 0.0% 0.4% 
ABC 3TC EFV n 5 79 84 
% 22.7% 36.2% 35.0% 
ABC 3TC STOCRIN n 1 1 2 
% 4.5% 0.5% 0.8% 
D4T 3TC EFV n 1 33 34 
% 4.5% 15.1% 14.2% 
AZT 3TC EFV n 0 7 7 
% 0.0% 3.2% 2.9% 
AZT 3TC KALETRA n 1 1 2 
% 4.5% 0.5% 0.8% 
D4T KALETRA 3TC n 1 28 29 
% 4.5% 12.8% 12.1% 
D4T 3TC ALLUVIA n 1 9 10 
% 4.5% 4.1% 4.2% 
AZT DDI ALLUVIA n 0 3 3 
% 0.0% 1.4% 1.3% 
AZT 3TC NVP n 0 5 5 
% 0.0% 2.3% 2.1% 
ABC EFV AZT n 0 1 1 
% 0.0% 0.5% 0.4% 
ABC 3TC ALLUVIA n 0 13 13 
% 0.0% 6.0% 5.4% 
AZT 3TC ALLUVIA n 0 4 4 
% 0.0% 1.8% 1.7% 
ABC D4T EFV n 0 1 1 
% 0.0% 0.5% 0.4% 
ABC AZT KALETRA n 0 1 1 
% 0.0% 0.5% 0.4% 
3TC MONOTHERAPY n 0 4 4 
% 0.0% 1.8% 1.7% 
AZT EFV KALETRA n 0 1 1 
% 0.0% 0.5% 0.4% 
ABC 3TC NVP n 0 1 1 
% 0.0% 0.5% 0.4% 
Total n 22 218 240 
% 100.0% 100.0% 100.0% 
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It can be seen from Table 3.11 that 35% of children on treatment were on the ABC, 3TC,  
EFV regimen but 50% of children who presented with lesions were on the ABC, 3TC,  
Kaletra regimen. However, due to a small set of responses that is unbalanced and responds to  
mostly single categories, means that we were unable to test for differences with HAART  
regimen and the presence of oral lesions. 
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CHAPTER 4: DISCUSSION 
 
It has been well established that oral lesions are often the earliest signs of HIV disease and  
are clinical markers for immunosuppression, HIV viral load and disease progression (3,12,14).  
Disease progression is monitored by serum CD4 
+ 
T-lymphocyte counts, which is used to  
assess immune competence; and HIV-RNA levels, which is used to assess viral replication.  
Therefore they are also used as indicators of immune and virologic failure or success in  
patients on antiretroviral therapy (58). Therefore, the presence of oral lesions in children on  
HAART, may present as clinical predictors of HAART failure and disease progression to AIDS. 
 
Studies conducted by Duggal et al, reported significant associations between CD4
+  
T- 
lymphocyte counts, viral loads and oral lesions. They, found that disease progression is most  
accurately measured by increasing viral loads, however, a lower CD4
+ 
T – lymphocyte count has  
a more significant association with the presence of oral lesions (6).  They also found a strong  
statistical association between the presence of oral lesions and children with low CD 4
+ 
T- 
lymphocyte counts (12). In contrast to this study, a study conducted by Gaitan-Cepeda et al,  
reported a significant association between oral lesions, in particular oral candidiasis and higher  
viral loads. They concluded that oral lesions may be associated with virologic failure in  
adolescents on HAART (7). In this study, the association of CD4
+ 
T-lymphocyte count and viral  
load at baseline to the presence of oral lesions was assessed and no significant association was  
found. Rwenyonyi et al (8) and Nabbanja et al (21), also found no influence of CD4
+ 
T- 
lymphocyte count on the presence of oral lesions but they experienced the same limitation as we  
did in our current study and that is that CD4
+ 
T-lymphocyte counts were obtained from the  
medical files retrospectively and could have changed drastically at the time of examination and  
diagnosis of lesions, therefore these findings need to be interpreted with caution. Our study  
found a weak, negligible association between CD4
+ 
T-lymphocyte count and viral load. This is in  
agreement with studies conducted by Sturt et al and Ramirez –Amador et al, who reported that  
increases in CD4
+ 
T-lymphocyte count is independent of the rate of virologic response (14,35). 
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In our study, 27% of children who presented with either intra-oral or extra-oral lesions, showed a  
decrease in the latest CD4
+ 
T-lymphocyte count from baseline and a significant improvement in  
reduction of the viral load with the introduction of HAART. One child presented with a decrease  
in CD4
+ 
T-lymphocyte count and an increase in viral load. The latter case may be deemed as  
HAART failure as there had never been a positive response to therapy. The other cases however,  
can neither be categorized as HAART failure nor IRIS; as in the case of IRIS patients need to  
show disease at a time of immunologic and virologic success. Signs and symptoms after HAART  
initiation that are indicative of an IRIS event includes prolonged fever, dyspnoea, abdominal  
pain, diarrhea, headache, weakness, lymphadenitis, subcutaneous nodules and abnormal skin  
lesions (59). HIV+ve individuals with or without IRIS, but presenting with the same  
infection or inflammatory condition, have similar clinical symptoms and laboratory results.  
Therefore, prior to making a diagnosis of IRIS, the clinician must rule out the possibility of  
delayed recovery of immune function, inadequate antimicrobial therapy for a pre-existing  
condition, drug resistance, drug toxicity and superinfection by other pathogens (60). 
 
In a study conducted in Thailand by Puthanakit et al, the incidence of IRIS amongst HIV+ve 
children was 19%. Twenty nine patients experienced thirty two episodes of IRIS.  Of these,  
43.7% were caused by Mycobacterium species, 21, 9% by the varicella zoster virus and 18.7 %  
were manifestations of herpes simplex labialis. The remainder of the cases comprised of cases of  
Cryptococcus neoformans, and one case of Guillan-Barré syndrome (59). In this study, a nine  
year old female patient presented with HSV labialis at week 4 (post HAART initiation), herpes  
dermatomal zoster at week 12 and Mycobacterium avium complex (MAC) pulmonary infection  
at week 26. Her baseline CD4
+ 
T-lymphocyte count was 44 cells/mm
3
, the reading, closest to the  
time of IRIS events, was 214 cells/mm
3. 
The viral load at baseline was 5.57 log10 copies/ml and
 
had decreased to 1.70 log10  copies/ml at the time of IRIS events. Despite, showing  
immunological and viral recovery, this patient died during the IRIS episode. This study also  
concluded that patients who developed IRIS had lower baseline CD4
+ 
T-lymphocyte percentages  
than those who did not develop IRIS (59). This is in agreement with a study conducted by 
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Tangsinmankong et al, who concluded that severe immunodeficiency at baseline and rapid  
immunologic and virologic response to HAART are risk factors for the development of IRIS. All  
the children in their study, presented with herpes zoster infection, with significant increases in  
CD4
+ 
T-lymphocyte numbers and percentages. Six out of seven children at the time of the IRIS  
event had viral loads ˂ 400 copies/ml(61). On the other hand, a study conducted by 
Wang et al, found that children who developed IRIS, had a higher baseline viral load and tested  
positive for indicators of malnutrition. They found no association between baseline CD4
+ 
T- 
lymphocyte counts and IRIS. The IRIS events included mycobacterium tuberculosis, Bacillus 
Calmette Guerin lymphadenitis, VZV and herpes labialis. They found a prevalence rate of 
20% (15), which is similar to the prevalence rate found in the study conducted by 
Puthanakit et al (59).The differences in association of CD4
+ 
T-lymphocyte counts and IRIS  
may be due to the smaller sample size in the study conducted by Wang et al (15). 
 
The cases in our study represent rather, discordant responses to therapy. Both forms of  
discordant responses that is immunologic or virologic, are predictive of mortality in HIV+  
patients on HAART (24). Ineffective immune restoration, that is, patients who present with  
decreased viral loads but no improvement or decreasing CD4
+ 
T-lymphocyte counts, is 
associated  
with progression to AIDS and non-AIDS diseases and malignancies (38). In a study conducted 
by  
Lapadula et al, the authors explain that a persistent state of immunosuppression increases  
susceptibility to opportunistic infections. Furthermore, there is a lack of immune surveillance to  
detect and destroy neoplastic cells, therefore, these patients are also more susceptible to  
malignancies (38). Those patients who are virologic non-responders are also at risk of increased  
mortality as sustained virologic suppression is necessary to maximize CD4
+ 
T-lymphocyte count  
and function (62). In a study conducted by Moore et al, immunological non-responders 
had a relative hazard (RH) of 1,87 and viral non-responders had an RH of 3,48 for mortality. 
Lack of adherence to therapy was found to be associated with both types of discordant 
 responses (62). Patients with incomplete adherence or those who are on suboptimal regimens are 
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more likely to have higher rates of mortality as they develop incomplete immunologic and 
virologic responses (63).This is indicated by the fact that patients who show > 95% adherence 
to therapy have an RH of 0.56 for mortality (62).In our study, the number of children  
presenting with lesions is low, however of these children with lesions, those presenting with  
concomitant discordant responses to therapy is high. This may account for the lack of association  
found between CD4
+ 
T-lymphocyte count, viral loads and the presence of lesions. Other factors  
such as the small sample size, the time lag between clinical examination with diagnosis of lesion 
 
and the latest CD4
+ 
T-lymphocyte count and viral load readings and duration of HAART; may 
also play a role in this.  
Therefore, the findings of this study must be interpreted with caution.  
 
The findings of this study are in contrast to a study conducted in a similar South African  
population by Duggal et al in 2010. Duggal et al found oral lesions to be associated with a  
lower CD4 
+ 
T –lymphocyte count and high viral loads, reporting a prevalence of 52% of oral  
lesions in children receiving antiretroviral therapy (12).Comparatively, our study reports a  
prevalence rate of 9,2% in 2014. It must be noted that the Duggal et al study had a significantly  
smaller sample size than our study (n=56). They reported OC, in particular  
pseudomembranous candidiasis, as the most frequently encountered oral lesion. 
 
Oral candidiasis has been recognized as having an association with decreased CD 4
+ 
T- 
lymphocyte counts and an increased risk of developing AIDS (12).This was also shown in a 
study conducted by Gaitan-Cepeda et al, who reported a 20% prevalence rate of oral lesions 
in adolescents on HAART and 30,6% prevalence rate in children on HAART.  They reported  
oral candidiasis as the most frequent oral opportunistic infection with a prevalence rate of 21,8% 
in their study (7). A study conducted by Pomarico et al is in agreement with the findings of these  
previous studies reported that HIV infected children had a higher prevalence of oral lesions;  
particularly oral candidiasis; than non-infected children. They also report a significant decrease  
in the prevalence of oral candidiasis in children on HAART (64). Two mechanisms were  
proposed: HAART results in reduced infection with immune reconstitution and  
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secondly medications included in the HAART regimen have direct anti-yeast effects. The latter  
statement relates in particular  to protease inhibitors which inhibit candida- secreted aspartic  
proteinases (SAPs),which interfere with the growth and pathogenicity of the  
microorganism (64).Most children at the Empilweni clinic are on HAART regimens containing  
PI’s and this may explain why no OC was detected in our study.  
 
Oral candidiasis was also the most prevalent lesion in a study conducted by Kumar et al,  
who reported a prevalence of 61.65% of oral lesions in children on HAART.  Oral candidiasis  
accounted for 20, 86% of lesions, with 16,56% for  angular cheilitis, 8,28% for necrotizing 
 ulcerative gingivitis, 7,66% for necrotizing ulcerative periodontitis, 5,53% for linear gingival  
erythema and 2,76% for aphthous ulcers (9). Rwenyonyi et al, found oral lesions in 67,8% 
of children on HAART but in contrast to the previous study, they found no linear gingival 
erythema, NUG, KS or atypical oral ulcerations (8).Similarly, we report no cases of KS. 
As reported in a study conducted by Cox et al, KS represents only 0.4% of malignancies related 
to HIV in children in the United States. This, however, is not true for the prevalence of KS in 
sub-Saharan Africa where previous reports show a 30% prevalence of HHV-8 in Botswana 
and 35% in Uganda (65).This indicates that even within sub-Saharan Africa, geographical 
differences in the prevalence of HHV-8 exists and although previous reports from South Africa 
have reported a much lower prevalence rate of 9% in comparison to other African countries, 
it may explain why we report no cases of KS. However it is possible that no cases of KS were 
detected in our study due to the small number of children presenting with lesions. 
 
Our study reports no cases of OHL, LGE, parotid enlargement and cervical lymphadenopathy  
but does report cases of MC (Appendix E), scarring as a result of RHI and FEH. 
 
Molluscum Contagiosum (MC) is produced by a member of the DNA poxvirus group and in  
children it is transmitted by nonsexual contact. It is a common finding in children regardless of 
 their HIV status.  This therefore makes it difficult to draw any correlations due to the ability of  
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the virus to spread among HIV negative populations that live in close proximity to each other 
(66). Diagnosis of recurrent herpetic infection was made by the visible scarring and history 
 offered by the child’s parent/guardian. We reported on those cases that presented with scarring  
as a result of previous disease as the lesions still occurred whilst the child was on HAART. 
 
FEH is strongly associated with HPV; and although HIV is not the causative agent for FEH,  
HIV infected patients are more likely to develop oral HPV infections, than non-infected patients 
(67). This is further supported by the findings of a study conducted by Pinheiro et al, who  
examined 50 HIV+ve children and 50 HIV-ve children between the ages of 3 and 13 years old. 
HPV DNA was detected in 12% of HIV+ve children and in 6% of uninfected children. They also 
reported that HPV DNA may present early in HIV infection (68). The primary mode of HPV 
transmission in adults is sexual intercourse (68). In children, HPV is transmitted directly by 
skin or mucosal contact; or indirectly from fomites, perinatally from an infected mother or by 
sexual abuse (69,70).Children born to HIV+ve mothers have a higher exposure to HPV during  
birth, as HIV+ve mothers have a 2-3 times higher prevalence rate with a higher HPV viral load 
than HIV-ve women (26). This is supported by studies conducted by Mammas et al, that also 
suggested that maternal HPV viral load is a determinant for HPV transmission to the neonate 
(70). HIV infected individuals show high risk sexual behaviour and due to multiple partners and 
exposures, they frequently acquire HPV. Another explanation for the high HPV detection in  
HIV+ve individuals could be the increased replication of HPV and/or persistence of HPV (68). 
This statement is further supported by Moscicki et al, who reported the rate of persistence of 
both high and low risk HPV types to be  higher amongst HIV infected women than HIV  
uninfected women(71). Syrjänen et al, reported that contamination of a newborn’s oral cavity  
with genital HPV from the mother’s cervix appears to occur commonly at birth or during the  
perinatal period. They also report that detection of HPV in mothers was strongly associated with 
HIV seropositivity (69).Furthermore, exposure to HPV may continue from the mother/parents 
during child care (71). Other studies have reported a concordance of HPV types detected in  
newborn babies and their mothers in the range of 57% to 69%. Therefore, these infants may  
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acquire HPV postnatally from kissing, siblings and fomites (72). 
 
In a study conducted in a similar Tanzanian population, Hamza et al in 2006, found that parotid  
gland enlargement was the most common lesion (19,6%), followed by OC (11,8%), KS (3,9%),  
OHL (3,9%), herpes simplex (2,7%) and oral warts (2%) (27). Although the methods of  
examination in this study were similar to those in our study, their findings are different to our  
reported results. We report no cases of parotid enlargement, OC, KS, OHL or oral warts (18). 
Hamza et al, also report that they found no significant change in the occurrence of oral  
lesions in children receiving HAART compared to those not receiving HAART ( Odds ratio  
=0.35). We report a significantly low prevalence of oral lesions in children on HAART (18).  
This may be due to a few differences in the study. Firstly, in the Tanzanian study, both adults  
and children were examined. Only 51 children between the ages of 2 and 17 years old were  
examined, of these 51 children, only 22 were on HAART. We examined 240 patients aged  
between one month to 14 years of age, all of whom were receiving HAART and therefore had a  
much larger sample size. Hamza et al, were also able to draw a conclusion that there was a  
significant association between the presence of oral lesions and CD4
+ 
T-lymphocyte count. This  
is an accurate finding in comparison to our finding of no association of CD4
+ 
T-lymphocyte  
count to the presence of oral lesions as they were able to carry out haematological tests at the  
time of clinical examination and lesion diagnosis. Due to a lack of funding at the  
Empilweni clinic we were unable to do this and had to rely on retrospective records which were  
at times taken > 6 months prior to examination. Another reason for the differences in findings  
may be the duration of HAART. In our study, the average patient had been on HAART for  
1444,5 days ( 4 years), whereas in the Hamza et al study, majority of patients had only been on  
HAART for one to six months. In a study conducted by Meless et al, the patients had been on  
HAART for a similar median duration of 4,6 years and also report a much lower prevalence of  
oral lesions at 8,3% in HIV+ children on HAART in West Africa (22).Similarly to our study  
they reported that oral lesions in this population still occurred, but rarely. In contrast to our study  
and the Hamza et al study, they reported no cases of herpes simples. 
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The Human Herpes Simplex Virus I (HSV) is usually associated with labial lesions. One child  
presented with scarring  as a result of previous herpes labialis (Appendix E) and one child  
presented with active herpes simplex involving the skin in the peri-oral and submental regions as  
well as an inoculation lesion on the tragus of the right ear. The prevalence of HSV-1 infection  
is known to increase progressively from childhood and is inversely related to the child’s socio-  
economic background (19,57). However, with involvement of herpes viruses in the oral cavity  
and surrounding facial skin, it is difficult to ascertain HIV or HAART as the cause, as other  
contributing factors such as the geographic occurrence of pathogens, climatic conditions,  
psychological stress and infectious diseases amongst HIV-uninfected peers do play a role.  
 
Our study, however, is in agreement with a study conducted by dos Santos Pinheiro et al in  
2012, which reported a high prevalence of infection caused by the Herpesviridae  
family in this population but has no association with immune suppression, viral load and  
HAART (19). Ten out of twenty two cases presented with extra-oral lesions and 80% of these  
lesions were caused by diseases related to the Herpesviridae family of viruses. Four children  
presented with either active lesions or scarring as a result of VZV (chicken pox) (Appendix E).  
The Human Herpes Virus 3(HHV 3) causes primary varicella, mainly in children. The distinct  
characteristic of persistence in latency and stimulus-based reactivation of herpes viruses, is the  
cause of Herpes Zoster (HZ), and may occur in cases of immunosuppression promoted by HIV  
infection (19). One child presented with scarring as a result previous of HZ (Appendix E).  
During the time of primary varicella infection, HAART is protective against developing HZ and  
is even less prevalent in those with varicella-specific IgG seroprotection (19). HZ has been found  
to occur in children with IRIS. However, in this study the child presented with virologic  
suppression with a baseline count of 90 000 copies/ml to a latest count of 24 034 copies/ml but  
presented with a drop in CD4 
+ 
T lymphocyte-count from 1300 cells/mm
3 
at baseline to 449  
cells/mm
3
 at the latest reading. Therefore, it is difficult to classify the child as having IRIS but  
rather a discordant response to antiretroviral therapy.  
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In a Nigerian study conducted by Adebola et al in 2012, the authors concluded that paediatric  
patients receiving HAART had a significantly lower prevalence of oral lesions. They also found  
OC; in particular angular cheilitis; to be the most prevalent lesion (20). This is in contrast to our  
study, where no OC nor angular cheilitis was detected. This difference in findings may be  
attributed to the differences in the HAART regimen. The HAART regimen in this study  
comprised of Stavudine, Lamivudine and Nevirapine only, with exclusion of PI’s.  
Although HAART regimens at the Empilweni clinic are dictated by protocols, we found a lot of  
variations in regimen but most of the regimens included a PI. As discussed previously, it has  
been reported in the literature that PI’s exhibit an anti-yeast effect and may account for the  
absence of fungal infections detected in our study. Adebola et al, found an increased prevalence  
of gingival/periodontal disease and reported that these lesions are more prevalent in Africa and  
Asia due to poor nutrition and inadequate oral hygiene measures (20). They found that 3, 8% of  
the population presented with salivary gland disease and 14,3%  presented with aphthous  
ulcerations (20). Our study, reports two cases of oral ulceration, one was diagnosed as a major  
aphthous ulcer and the other as an ulcer of unknown origin. Aphthous ulcers are common among  
HIV-infected children and tend to be larger and more painful than in HIV uninfected children.  
The aetiology of these ulcers is unknown but may be attributed to the adverse effects of 
antiretroviral drugs or deficiency of vital nutrients (73). We were unable to determine the type 
of ulcer in the ulcer of unknown origin case as at the time of examination, the ulcer was in 
the healing stage and no obvious history could be provided by the patient or guardian. 
Adebola et al also reported two cases of KS and no cases of OHL. In comparison to other studies 
at that time, they reported a decreased prevalence of oral lesions, in particular OC and HIV-  
associated gingivitis (20). HIV-associated gingivitis was not reported in our study. The  
differences in these findings may be attributed to different social and geographical variations 
in the disease presentations. Furthermore, Adebola et al based their diagnosis of oral 
manifestations on the diagnostic criteria described by the USA Oral AIDS Collaborative Group 
 (1992), whereas our diagnoses were based on the review of OHARA: updated case definitions 
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of oral disease endpoints (2009). 
 
In a study conducted in India by Ponnam et al in 2012, a prevalence rate of 43% of children on  
HAART presenting with oral lesions was reported. Lesions included OC, ulcerative stomatitis,  
dental caries, gingivitis, periodontitis, HAART induced pigmentation and one case of mucocoele  
(73). This study found six cases of children presenting with hyperpigmentation in the oral cavity  
and accounts for 50% of the intra-oral lesions detected. The clinical appearance of oral  
hyperpigmentation is single or diffuse multifocal brown/black melanotic macules that appears in  
the mucosa, particularly buccal mucosa (74). This manifestation is difficult to diagnose and other  
causes such as racial pigmentation need to be excluded on the basis of a recent onset as described  
by the patient or a care-giver and the site of occurrence (74). It is also important to take a  
thorough history to exclude other clinical causes of pigmentation such as smokers melanosis,  
Albright’s disease and neurofibromatosis (75).  
 
Baghirath et al , found oral hyperpigmentation to be the second most prevalent oral  
manifestation, after oral candidiasis, amongst paediatric patients on ART. In this study, they  
found prevalences of 5,6% of children on short term ART and 12,5% of children on long term  
ART. No hyperpigmentation was observed in HIV+ve children who were not on ART but  
presented with other lesions and no hyperpigmentation was detected in HIV-ve children (76).  
Taiwo et al, conducted a study on the impact of HAART on oral lesions in adult patients and  
also found oral hyperpigmentation to be the second most common lesion following oral  
candidiasis, with a prevalence of 18,3% (77). Oral hyperpigmentation constituted 50% of intra- 
oral lesions or manifestations detected in our study. This pigmentation is thought to be drug  
induced, particularly in patients on regimens containing Zidovudine (27,31). However, studies  
conducted by Sontakke et al, found oral hyperpigmentation in  HIV +ve  individuals, who were  
not on any medications suggesting that medications that form part of ART/HAART regimens are  
not the only causative factor (78).  
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Oral melanin hyperpigmentation may be caused by antiretroviral medications such as  
Zidovudine or antifungals such as Ketoconazole, but it may also be caused by HIV-induced  
cytokine dysregulation, adrenocortical deficiency, which is common in HIV+ve individuals or it  
may be idiopathic ( 6, 18, 75). 
 
Feller et al, also explained that HIV-induced upregulation of IL-1, IL-6 and TNF-α promotes the  
production of α-melanocyte-stimulating hormone (α-MSH) by oral melanocytes with an  
increased production of melanin resulting in HIV-induced oral melanosis.  Cytokine  
dysregulation may follow path with decreasing CD4
+ 
T-lymphocyte counts and is frequently  
observed in patients with CD4
+ 
T-lymphocyte counts ˂ 200 cells/mm3. This is supported by  
studies conducted in ART-naïve patients by Namakoola et al, who also found that oral  
hyperpigmentation was significantly associated with CD4
+ 
T-lymphocyte counts ˂ 200  
cells/mm
3 
(79). However, other studies conducted by Umadevi et al, report that increased oral  
hyperpigmentation occurred in patients with CD4
+ 
T-lymphocyte counts > 200 cells/mm
3
 in  
both HAART ( 43,8%) and non-HAART (14,8%) groups of adults, suggesting, as in prior  
studies, that it may be due to Zidovudine therapy (74).Another proposed etiology is that  
mucosal inflammation can promote melanin pigmentation. There are more immune- 
inflammatory cells in subepithelial connective tissue of HIV+ve  individuals, even in clinically 
healthy mucosa, and these inflammatory or post-inflammatory states may contribute to  
hyperpigmentation of the oral mucosa (75). We attribute the varying prevalences and  
findings from our study and other studies, to the fact that the occurrence of this manifestation  
may vary according to different geographical locations (79), race – pigmentation  
is more commonly seen in dark-skinned people (75) and that it is not only drug-induced  
but may be due to other factors (75). 
 
Oral hyperpigmentation is not included in the case definitions of oral disease endpoints by the  
OHARA group.  At the 7
th
 World Workshop on Oral Disease in HIV/AIDS in Hyderabad, 2014;  
oral hyperpigmentation was a controversial topic. Some clinicians/ researchers are of the belief  
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that hyperpigmentation is merely a side effect of the drug and should not be described as an oral  
manifestation of HIV/AIDS. However, half of the children in our study who presented with an  
intra-oral lesion presented with hyperpigmentation and the authors of this report deem it  
necessary to report on this finding. Side effects or adverse drug reactions that alter a patient’s  
appearance or aesthetic appeal, are not only cosmetically and psychologically challenging, but  
may also decrease adherence to therapy. This in turn can cause potential drug resistance and  
treatment failure(63). Sharma et al, report 71,1% of adverse drug reactions in their  
study with nail hyperpigmentation being the most common adverse reaction detected (80). 
Studies conducted by Borrás-Blasco et al, concur with this and report that 80% of HIV+  
individuals experience adverse drug reactions such as rashes, hyperpigmentation, hair loss and  
hypersensitivity reactions at some point in therapy. They report that adverse drug reactions rather  
than treatment failure causes patients to discontinue HAART within the first year of treatment 
(81). 
 
Although mucocutaneous hyperpigmentation is not life threatening, it has a negative effect on  
the quality of life of HIV+ve individuals, which can lead to compromised adherence to drugs,  
suboptimal drug levels, which causes incomplete viral suppression and decreased CD4
+ 
T- 
lymphocyte counts, and the development of drug resistance. All of these factors lead to failure of  
ART regimens and compromises future therapy for these patients (63).This is particularly  
important in the population we have studied. The way in which a patient views the severity of  
this side effect/ manifestation is based on different characteristics, one of which is age.  Many of  
the patients in our study were adolescents or children soon to approach adolescence, a time when  
appearance becomes of increasing importance to the individual.  Therefore, to dismiss findings 
 of oral hyperpigmentation in our study would be an underestimation of its potential harmful 
 effects not only on the quality of life of the patient but also on treatment. 
 
Furthermore, one child presented with a hypersensitivity reaction to Bactrim. This reaction is due  
to the drug and is unrelated to the HIV or immune status of the patient. However, HIV-infected  
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patients are predisposed to developing drug-induced eruptions due to their altered immune  
function and defective metabolism of drugs (82). 
 
This study found no association with age at diagnosis of HIV but a significant statistical  
association with current age and the presence of lesions. Furthermore, an assessment of the  
correlation between presence of oral lesions and duration of HAART revealed that the average  
number of days on HAART was 1444,5 days ( 4 years), however, no significant association  
could be made between the length of time on HAART and the presence of oral lesions. The mean  
age of children presenting with lesions was 10,7 years. Only children under the age of 14 were  
assessed in the study as this allows us to compare our findings to other studies in a similar age  
group. Up to the age of 14, no difference in HIV prevalence by gender is observed suggesting  
vertical transmission. Children older than the age of 14, show a higher prevalence of HIV in  
females compared to males, reflecting the increased risk of infection in females via horizontal,  
sexual transmission (83). However, no route of transmission can be assumed as non-vertical  
(horizontal) routes of transmission by blood transfusion, surgery, exposure to sexual abuse and  
the use of unsterilized sharp objects for example during circumcision, do occur (84). In our  
study, there was no evidence in the patient’s files of a history of sexual abuse, sexual activity and  
blood transfusions; which leaves vertical transmission as the most likely route of transmission. 
Mother to child transmission (MTCT), may occur in utero with a transmission rate of 5-10%; 
intrapartum at 10-20% or through breastfeeding at 5-15%. In the absence of antiretroviral  
prophylaxis, majority of HIV transmission occurs at the time of delivery (10).  
 
There is an age-dependent difference in the progression of HIV disease between the adult and  
paediatric population (5, 7, 8, 910, 11). This is because perinatally acquired infection occurs  
during an important time of immune development and disrupts this dynamic process. The infant  
is reliant on the maternal immune system for protection and immune guidance as transplacental  
antibodies and breastmilk contain immunomodulatory molecules that stimulate growth and guide  
the child’s immune development. These early maternal influences have lifelong effects on  
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immune response but in the case of HIV infection, is perturbed (10). Disease progression in  
infants, due to the immature immune system, is faster due to a shorter incubation period. Without  
antiretroviral therapy there is a 50% probability of death by the age of 2 years (3,83,85,).  
Regardless of CD4
+ 
T- lymphocyte count or plasma HIV-RNA levels, younger children are at a  
greater risk of death and disease progression than older children (35). Many studies have  
reported that oral lesions are predictors of disease progression. Gaitan-Cepeda et al, report that  
oral lesions, in particular oral candidiasis, have a significant association to viral failure in HIV+  
children and adolescents on HAART (7).In contrast to this, Hamza et al, found the presence of  
oral lesions in patients receiving HAART and those not receiving HAART, correlates with of  
CD4
+ 
T- lymphocyte count ˂ 200 cells/mm3 (18). Miziara et al, reported that oral lesions had  
moderate sensitivity, high specificity and positive predictive value to predict immune failure. It  
also has low sensitivity, high specificity and positive predictive value to predict virologic failure.  
They concluded that oral manifestations of HIV are important markers of immune and virologic  
failure in children on HAART (58).However, Patton et al, argue that the usefulness of oral  
lesions as signs of disease progression or ART failure in compounded by IRIS, adverse reactions  
to medications that are part of the HAART regimen and the direct effect of some medications on  
oral lesions e.g. the anti-candidal effect exhibited by PI’s (86).Although lesions such as OC, KS  
and OHL, are indicators of a failing immune system, identification of oral lesions should not  
replace repeated CD4
+ 
T- lymphocyte count and regular viral load assessments to monitor  
treatment (86). Oral lesions were detected in older children in this study. This may be  
due to the evolution of prevention of mother to child (PMTC) strategies over the past ten years   
(26,87). 
 
Widespread implementation of highly effective HIV interventions began in the 1990’s in  
developed countries. However, antiretroviral prophylaxis for prevention of mother to child  
(PMTC) HIV transmission only became available in Africa around 2004.South Africa began a  
free ART national roll out in the same year (88). Thereafter, protocols were developed for  
improved implementation of PMTC strategies and paediatric antiretroviral drugs became more  
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widely available (83). In South Africa, by 2011, PMTC HIV programs had reduced perinatal  
transmission to 2,7% (83). Patients who failed to benefit from PMTC programs but had early  
maternal and infant diagnosis are at an advantage because effective early antiretroviral therapy is  
associated with early virologic suppression which is associated with normalization of B and T  
cell numbers and function (10). Also, increased thymic function in HIV-infected children  
enhances their immune recovery and they are able to fight infections better than those who are  
diagnosed later in life with delayed initiation of HAART (10). Furthermore, latent viral  
reservoirs are established early in infection but early initiation of therapy minimizes the extent of  
these viral reservoirs. HIV+ paediatric patients who initiate HAART within the first few months  
of life have lower levels of proviral HIV DNA and lower levels of replication-competent virus in  
comparison to children who received treatment later in life (10). This may be significant to this  
study as it may account for the prevalence of lesions in children around the age of 10, who at the  
time of initial infection may not have benefitted from early initiation of HAART, whereas the  
younger children in the study did benefit from early maternal diagnosis due to PMTC programs  
and early implementation of HAART. However, due to the small number of patients presenting  
with lesions with no evidence of association to CD4+ T-lymphocyte count and viral loads, this  
deduction should be interpreted with caution. 
 
South African PMTC guidelines were aligned with WHO guidelines of PMTC in 2010 and the  
program is reported to have 98.9% coverage for antenatal HIV testing, 78,3% CD4 
+ 
T- 
lymphocyte count testing, 91,8% antiretroviral prophylaxis to mother and/or baby and 89%  
feeding advice (17). Despite great improvements in PMTCT in South Africa, the prevalence of  
HIV amongst pregnant woman is still high. This may be due to a few factors; the first is that  
most women present for their first antenatal visit after 14-16 weeks gestation. However, 12-16  
weeks of maternal antiretroviral therapy is required, depending on the viral load, to achieve viral  
suppression at the time of delivery. This results in suboptimal prevention of transmission (17).  
Furthermore, HIV may be acquired during the pregnancy and postpartum, which will not be  
detected unless repeat testing is done. Lack of retesting misses the opportunity of maternal  
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diagnosis and has increased risk of mother to child transmission (MTCT) because of high HIV  
viral loads during primary infection (89). In South Africa, 4% of women who test HIV – ve 
initially, become HIV+ve later in pregnancy. Therefore re-testing is essential to detect any  
seroconversion during pregnancy and breastfeeding (90).Social issues such as perceived poor  
quality of services at clinics, financial constraints and distance from local clinics are all  
contributing factors to women not seeking antenatal care (11). A study conducted in Malawi by  
Braun et al, suggests that PMTCT, early infant diagnosis and paediatric ART are  
not sufficiently integrated. The loss of follow up or delay in ART initiation may be due to the  
fact that HIV-infected mothers receive ANC and maternal care at one location but have to attend  
a different location for paediatric care. The cost of transport impedes infant HIV test follow up 
(91). Silal et al, report that in South Africa, over 90% of women utilize maternal health services.  
However, barriers to access of obstetric care remain. Besides the location of facility and costs of  
treatment, the attitudes of care-givers plays a large role in determining the influx of women  
seeking care. Health care for pregnant women and infants is free, which is a positive for women;  
however the increased workload linked to free services impacts negatively on the staff morale.  
This results in poor staff engagement and contributes to women not wanting to return to a facility  
for delivery or future treatment (92). Late initiation of HAART in children may also be due to  
maternal factors such as feelings of guilt, denial and “lack of readiness” (17). As reported by 
 Technau et al in 2014, 91.8% of infected mothers and their children received PMTC,  
however, in 52% of this population, prophylaxis was started late, not started according to the  
guidelines or there was poor adherence to therapy (17). Similarly, this study found discrepancies  
between age of diagnosis of HIV and initiation of HAART. Age of diagnosis in this context may  
not be of significance due to the psychological and socio-economic stigma related to HIV as  
explained above. Furthermore, Hsiao et al, also report on a delay between the first HIV  
polymerase chain reaction (PCR) and the first viral load testing date (done as part of the ART  
work-up). They reported a median delay of 146 in 2005, 81 days in 2007, 39 days in 2008 and 33 
 days in 2010 (26). 
The authors attribute this delay to a few reasons. Firstly, PCR testing is expensive, time  
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consuming and requires specialized laboratory equipment. Secondly, issues of conducting HIV  
testing in primary health care centres, transporting specimens to these laboratories and the return  
of results back to the centre, at which stage may require referral of the infant to another centre  
also causes delay. 
 
Thirdly, in this study, only 57% of mothers returned to the facility to receive the results (26). 
A report by Creek et al, also states that in resource-limited settings, difficulty in returning results 
quickly to a health centre may cause results to go unclaimed (93).The National consolidated 
guidelines for PMTCT of HIV and the management of HIV in children, adolescents and adults, 
which was updated in December 2014, also recognizes linkage of HIV+ individuals after 
testing positive to continuous care as a problem. The guidelines explain two main time periods 
when patients are lost: 1) Between testing HIV+ve and the first CD 4
+ 
T-lymphocyte count 
test and 2) Between the first CD 4
+ 
T-lymphocyte count test and the return visit to obtain results 
(90).They attribute this loss of patients to barriers including having to travel long distances 
to the clinic, long waiting times at the clinic, clinic staff shortages, inability to take time off 
work, lack of full understanding of the treatment plan ,and fear of stigma and discrimination 
(90).Hsiao et al, explain the non- return of mothers to receive results to be partly due to the 
migratory patterns of women during pregnancy and postpartum. Women, in South Africa, are 
known to migrate to urban centres for ANC and maternal care but return to rural areas after 
giving birth (26).   
 
Therefore timely diagnosis of HIV in children does not necessarily incur timely linkage to 
 treatment and the implementation of HAART. We would expect children who are diagnosed  
early to receive treatment early and thus experience less mortality including oral lesions. 
However, in our study we did not find an association between age at diagnosis of HIV and the 
presence of oral lesions, as HAART; which is responsible for reducing mortality, is not  
necessarily implemented early, even in cases of early HIV diagnosis. This observation, whilst 
 true for some, may not be true for all subjects. This may however, explain the failure to find an  
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association between age at diagnosis of HIV and presence of oral lesions in our study. 
 
Our study has several limitations. Firstly, none of the patients who were referred for biopsy  
presented for biopsies and so diagnoses of lesions were based on clinical appearance and history  
offered by the child’s guardian/parent. At times, the guardians/parents could not give exact  
timings as to when the lesions occurred  but confirmed that children were on antiretroviral  
treatment when these lesions occurred. This means that the lesions seen could not be attributed to  
immunologic or viral response to HAART. Furthermore, lesions like ‘chicken pox’ and MC 
occur in uninfected children of the same age and may not necessarily be attributed to HIV or  
HAART. Data available for the latest CD4
+ 
T-lymphocyte count or viral load was at times over 
6 months old and did not reflect the child’s immunologic and virologic status at the time of the 
lesion as the clinic has limited funding available for repeat laboratory testing. This made it  
difficult to identify possible cases of IRIS.  Furthermore, correlation analyses was difficult and  
not possible due to the low prevalence or low sample size ( n=22) of children presenting with  
intra/extra- oral lesions. With these limitations, the results of this study should be interpreted  
with caution. 
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CHAPTER 5: CONCLUSION 
 
This study, in comparison to other African and International studies, reported a relatively low  
prevalence of 9,2% of  oral lesions in paediatric patients on HAART. This might highlight the  
success of HAART administration in HIV+ children. Oral hyperpigmentation accounted for 50%  
of the intra-oral lesions detected. Other intra-oral lesions found included focal epithelial  
hyperplasia (25%), recurrent herpetic infections (8,3%) , major aphthous ulcer (8,3%) and ulcer  
of unknown origin (8,3%). Extra-oral lesions were also detected and 80% of these lesions were  
caused by the Herpesviridae family of viruses including herpes simplex, herpes varicella zoster,  
and herpes zoster. The study also reports no significant association between CD4
+ 
T- lymphocyte  
count, viral load, HAART regimen or duration of HAART and the presence of oral lesions. Due  
to the small number of lesions and many HAART regimens, statistical associations could not be  
made. No significant association was detected between age at diagnosis of HAART and the  
presence of oral lesions; however, a significant association was detected between current age and  
the presence of lesions. In this study, the age of diagnosis often did not match the time of  
HAART initiation and this may be related to maternal influences which include the fear of  
discrimination and stigmatization; and feelings of guilt or denial. The significant association  
between current age and the presence of oral lesions could be an indicator of the progress made  
in PMTCT strategies, early maternal and infant diagnosis and early implementation of HAART   
over the last ten years in South Africa. However, further research should be conducted on  
discordant responses to therapy in the paediatric population. We also recommend oral  
examinations to be conducted regularly by clinicians with improved record keeping. 
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APPENDIX B 
Information Sheet in English 
Hello,  
My name is Dr A Bhula from the Department of Oral Medicine and Periodontology at the 
University of the Witwatersrand.  You are receiving this information sheet as a parent/ legal 
guardian to a child that is HIV positive. We are doing a study to find out what types of lesions 
occur in children on HAART.  As part of the study we will also record the viral load and the 
CD4 count. Oral lesions associated with HIV infection are common and can be caused by many 
factors e.g. bacterial, viral and fungal infections and can affect various parts of the mouth for 
example, the tongue, the gums, the palate or the lips.  They can also present as lumps or ulcers.  
However, these lesions are less commonly seen in patients on ARV’s (HAART), and if they are 
seen in patients on HAART it should raise concerns.  The results of this study could enable the 
medical workers to pick up these problems earlier, and might form a helpful diagnostic aid in 
resource poor areas where facilities are lacking. 
Being in this study will not negatively affect the child in any way.  The child’s name will not be 
recorded on the data sheet, and the information provided by you and that taken from the child’s 
file will remain strictly confidential.  Therefore no one will be made aware of your child’s HIV 
status or be able to tie him / her to the completed data sheet. 
If you do agree to allow your child to participate in the study, the oral examination will be done 
first thing on the morning of the routine clinic visit.The oral examination will include taking 
photographs of the lesions detected in the child’s mouth without revealing his/her face and 
identity. This will ensure that the child does not lose his/her place in the queue and his/her 
treatment from the HIV clinic is not negatively affected in anyway.  You will also have to sign 
the informed consent form, answer a few questions asked by myself and allow me to access 
information in the child’s file.  You will also have to allow me (Avni Bhula) to examine his/her 
mouth, which will take about 5min. 
 
If the child presents with HIV-associated oral lesions we may have to draw blood to assess for 
CD4+ T cell counts and viral loads, should these not be on file or too old.  No more than 5ml of 
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blood will be drawn, as is done with regular CD4+ T cell counts and viral load testing.  5ml is 
equal to one teaspoon of blood. There is little to no risk associated with drawing blood, but there 
is a chance that the area where we draw blood from may be tender afterwards.  The child will 
then be referred to the Oral medicine clinic at Wits to have the oral lesions managed. If required, 
a small piece of the lesion will be taken and sent to the lab for testing (biopsy) to aid the 
personnel at the clinic in the diagnosis. The biopsy will be performed by the doctors at the Wits 
Oral medicine clinic, and there may be some discomfort and mild swelling after the procedure, 
but painkillers will be provided. If tooth decay or other lesions affecting the skin are detected, the 
child will be referred to the dentist or to the Dermatology clinic respectively for treatment. 
The oral examination will be of great benefit to the child as it will allow us to detect and refer for 
treatmentof oral lesions if we find any, thus improving comfort and function. Participation in the 
study is not compulsory.  If you do not wish your child to participate in this study, the treatment 
he / she is receiving from the HIV clinic will not be affected at all, and an oral examination can 
still be conducted if you wish. Should you have any questions regarding the study you can 
contact me (Dr Avni Bhula) at 0823144299 or by email to bhula_a@yahoo.com. If you are 
unhappy about the way your child has been treated at any point during this study you can contact 
the chairperson of the Human Ethics Research Committee, Professor P Cleaton-Jones at 
011 7172301. 
Thank you for your assistance 
Dr A Bhula 
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Informed Consent Form 
 
I have been informed about the study being conducted and agree to have my child participate in 
this study.   
 
Name:  ________________________________ 
 
Signature:  _________________________________ 
 
Date:  ______________________ 
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Information sheet in Zulu  - Iphephalesaziso 
 
Sawubona 
IgamalaminginguDokotelaAvni 
Bhula.Ngenzaucwaningongezilondaezingatholakalaemulomeniwezinganeezisebenzisaimishangu
zoelwisaigciwanelengculazi.Ngikubhalelalesisazisonjengomzali, 
nomanjengomuntuomdalaonelungelolokunakekelainganeephilanegciwanelengculazi. 
Ekwenzenilolucwaningosizobhekisisaukwandakwaleligciwanelengculaziegazini (viral load), 
kanyenokwehlakwamasoshaegazi (CD4 count), 
umasizitholaizilondaemulomeni.Lezizilondazingabangwaamagciwaneahlukahlukenefuthizingave
laezindaweniezihlukenezomlomo.Zingavelaolimini, 
ezinsininiolwangeninomaezindebenizomlomo.Zingabonakalanjengezilondakumbeamaqhubu. 
Lezizilondaazivamisileukuphathaabantuabasebenzisaimishanguzoeyelaphaingculazi (ARVs);  
futhiukubonakalakwazokubantuabasebenzisalemishanguzoakwamukelekile. 
Lolucwaningoesilwenzayolubalulekilengobalungasizaukuthiukungasebenzikahlekwemishanguzo
kusheshekubonakale.Imiphumelayalolucwaningoizosizanabasebenzibezempiloukuthibashesheba
zibonelezizinkinga, 
ikakhulukaziezindawenilaphoubuxhakaxhakabemishininezidingozokuhlolazingekhokhona. 
Ukubayingxenyeyalolucwaningongekekuyihlukumezeinganenomangayiphiindlela.Igamalengane
ngekelidalulwe, 
kantifuthinemininingwaneozosinikayonakanyenaleesizoyitholaefayilinilakhoizovikelekakuwowo
nkeamaphephaesizowasebenzisa.Ngakho-keakekhoumuntuozokwazingesimo se HIV 
sengane.Uma 
uvumaukubainganeyakhonomaoyinakekelayoibeyingxenyeyalolucwaningokuzofanelaukuthiusay
indephansiukuthiuyavumafuthiusinikezanegunyalokuthisiyihloleumlomo, 
sisebenziseimininingwaneesefayiliniyayolasesibhedlelanokuthiyonkeimibuzoesizokubuzayonauz
oyiphendulangeqiniso. 
84 
 
Uma sitholaukuthiinganeinezilondaezihambisananokusulelekangegciwanelengculazi, 
nomayiluphiolunyeuhlobolwezilondakambeukugula, 
sizoqinisekisaukuthiitholausizoeklinikiyamazinyo, 
futhiitholenamakhambiokwelaphaizilondangokusemandleniethu.Kungenzekasidingeukuthathaiga
zielincaneelingangethisipuniukuzesikwaziukuhlolaisilinganisosamasoshaegazi (CD4 count), 
kanyenesegciwanelengculazi (viral load) 
egazinilenganeumangabelemininingwaneingekhokambeefayiliniwenganewasesibhedlelakumbeiz
iphumozalemininingwaneezisefayilinilenganezizindalakakhulu.  Ukuthathaigaziakunabungozi, 
kodwakungenzekauzwekungemnandilaphosithathekhonaigazi.Uma 
kunesidingosizosikaisicubuesincanesesilondaesizocwaningwangochwephesheukuzesiqinisekiseu
kuthikungabeinhloboniyesilonda.Imina (AvniBhula) 
ozosikalesisicubu.Kungenzekakuvuvukalefuthikubebuhlungwanalaphosisikekhonaemvenikwesik
hathi. 
Ukuhlolwakomlomowenganekuzobayinzuzoenkuluenganeni, 
ngobakuzosizaukuthiitholeumshanguzooqondenenezilondaezikuvelaemlonyeningokushesha.Uku
hlanganyelananathingokuvumaukubaingxenyeyalolucwaningoakuphoqiwe, 
futhiakunanzuzoenjengemali.Umaungavumiukuthiinganeibeyingxenyeyalolucwaningo, 
izoqhubekaitholeukwelashwaekliniki ye HIV, ngekelokhokuphazamiseke, 
nokuhlolwakomlomokuzoqhubekamawufisakuqhubeke. 
Ucwaningoluzothathaimizuzuemithathukuyakwemihlanu.Ucwaningoesilwenzayoluzoqalaekusen
imanifika, ngaphambikokubakuqaleiklinikiyegciwanelengculazinjengokwejwayelekile, 
lokhukuzokwenzaukuthiinganeingalahlekelwaindawoyayoemgqeniwaseklinikifuthikungabinoku
phazamisekakokuhlolwakwayo. 
Uma udingaukwazikancononomaimininingwanemayelananocwaningo, 
ungesabiukufonaubuzekuDokotela A. Bhula – 0823144299, nomai-email bhula_a@yahoo.com. 
Uma udingaukusitshelaukungakuphathangakahlekulolucwaningoungafonelaiREC 
administratorusihlalouNjingalwazi P. Cleaton-Jones 011 717 2635. 
Ngiyabongangosizolwenu 
Dokotela A. Bhula 
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Imvume 
 
Ngichazelwengocwaningoolwenziwayo, futhingiyavumaukubaingxenyeyalolucwaningo. 
 
Igama: ____________________________________ 
 
Ukusayina:_________________________________ 
 
Usuku:_____________________________________ 
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APPENDIX C 
Minor Assent Form 
 
Hello, 
My name is Avni Bhula, I am a dentist. Dentists take care of teeth and any other problems in the mouth. 
You are taking medication to help you feel good and we are studying how well these medications are 
working and if they affect your mouth.  
We would like to look into your mouth and check if there are any sores or ulcers. This will take 5 minutes 
and we will be using a light and a wooden spatula. There are no injections or anything else that will 
make you sore. Your parents or the adult you are here with will be with you during the time I look into 
your mouth. We will also be explaining to them and asking them for permission.  
Your age and results from your blood tests will be taken from your file but we will not take your name. 
This means nobody will be able to know it was you we have examined. If you do have a sore in your 
mouth, we will be asking permission to take a photograph. 
If we do find something wrong in your mouth, we will send you to the doctors and dentists who will be 
able to help with this so that you can eat and speak comfortably again. This will also help your medical 
doctor know if the medications you are taking is helping you. If your doctor feels the medication is not 
helping then he/she may take a blood test, as you have had before.  
You do not have to take part in the study if you do not want to. It is not compulsory and will not affect 
your treatment that you have been receiving from the clinic.  
 
Yours Sincerely, 
Dr. A. Bhula 
Do you allow me to check your mouth? 
Please tick:  
 
 
 
Initials or name:  
 
 
 
NO YES 
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APPENDIX E 
Photographs of child presenting with scarring as a result of Herpes Zoster with ophthalmic  
involvement of left eye: 
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Photographs of child presenting with molluscumcontagiosum: 
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Photograph of child presenting with scarring as a result of herpes labialis: 
 
 
 
Photograph of child presenting with active Herpes Varicella Zoster ( healing stage): 
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